JP2008510714A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510714A5
JP2008510714A5 JP2007528011A JP2007528011A JP2008510714A5 JP 2008510714 A5 JP2008510714 A5 JP 2008510714A5 JP 2007528011 A JP2007528011 A JP 2007528011A JP 2007528011 A JP2007528011 A JP 2007528011A JP 2008510714 A5 JP2008510714 A5 JP 2008510714A5
Authority
JP
Japan
Prior art keywords
vla
composition
binding antibody
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007528011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510714A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/029407 external-priority patent/WO2006023651A2/en
Publication of JP2008510714A publication Critical patent/JP2008510714A/ja
Publication of JP2008510714A5 publication Critical patent/JP2008510714A5/ja
Withdrawn legal-status Critical Current

Links

JP2007528011A 2004-08-20 2005-08-18 多発性硬化症の長期処置 Withdrawn JP2008510714A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60347004P 2004-08-20 2004-08-20
US60346804P 2004-08-20 2004-08-20
US60349504P 2004-08-20 2004-08-20
US61602304P 2004-10-05 2004-10-05
PCT/US2005/029407 WO2006023651A2 (en) 2004-08-20 2005-08-18 Extended treatment of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011253859A Division JP2012036225A (ja) 2004-08-20 2011-11-21 多発性硬化症の長期処置

Publications (2)

Publication Number Publication Date
JP2008510714A JP2008510714A (ja) 2008-04-10
JP2008510714A5 true JP2008510714A5 (enExample) 2008-08-21

Family

ID=35968170

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007528011A Withdrawn JP2008510714A (ja) 2004-08-20 2005-08-18 多発性硬化症の長期処置
JP2011253859A Withdrawn JP2012036225A (ja) 2004-08-20 2011-11-21 多発性硬化症の長期処置
JP2012001065A Pending JP2012067139A (ja) 2004-08-20 2012-01-06 多発性硬化症の長期処置
JP2014252699A Pending JP2015052022A (ja) 2004-08-20 2014-12-15 多発性硬化症の長期処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011253859A Withdrawn JP2012036225A (ja) 2004-08-20 2011-11-21 多発性硬化症の長期処置
JP2012001065A Pending JP2012067139A (ja) 2004-08-20 2012-01-06 多発性硬化症の長期処置
JP2014252699A Pending JP2015052022A (ja) 2004-08-20 2014-12-15 多発性硬化症の長期処置

Country Status (6)

Country Link
US (5) US20090010926A1 (enExample)
EP (2) EP1789086A4 (enExample)
JP (4) JP2008510714A (enExample)
AU (1) AU2005277343B2 (enExample)
CA (2) CA2478458A1 (enExample)
WO (4) WO2006023649A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
JP4871355B2 (ja) 2005-05-12 2012-02-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 無線メッシュネットワークのための分散型学習方法
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
RS20080391A (sr) * 2006-03-03 2009-07-15 Elan Pharmaceuticals Inc., Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom
US20100150915A1 (en) * 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
RS63744B1 (sr) 2010-01-11 2022-12-30 Biogen Ma Inc Test za antitela protiv jc virusa
PT2558499T (pt) 2010-04-16 2017-07-14 Biogen Ma Inc Anticorpos anti-vla-4
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CN103732062A (zh) * 2011-05-26 2014-04-16 比奥根艾迪克Ma公司 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
ES2729945T3 (es) 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
JP5711167B2 (ja) 2012-02-22 2015-04-30 三ツ星ベルト株式会社 アラミド心線及び伝動ベルト
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
HU196394B (en) * 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0670735B1 (en) * 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6432404B1 (en) * 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
JP2001527040A (ja) * 1997-12-30 2001-12-25 バイオアブソーバブル コンセプツ，インコーポレイティド 神経系の脳血管性疾患を治療、抑制及び防止するためのテトラサイクリン及び／又はテトラサイクリン誘導体
US20040107368A1 (en) * 1998-06-04 2004-06-03 Z4 Technologies, Inc. Method for digital rights management including self activating/self authentication software
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US7194092B1 (en) * 1998-10-26 2007-03-20 Microsoft Corporation Key-based secure storage
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
IL139321A0 (en) * 1999-03-03 2001-11-25 Biogen Inc Methods and compositions for modulating lipid metabolism
WO2001045725A2 (en) * 1999-12-23 2001-06-28 Ancile Pharmaceuticals, Inc. Treatment for inflammatory bowel disease (ibd) and related conditions
AU2001245899B2 (en) * 2000-03-31 2006-06-15 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US20070122406A1 (en) * 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US20040141947A1 (en) * 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
KR20050114212A (ko) * 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
ZA200506159B (en) * 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
JP2007532681A (ja) * 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド Ｂ細胞の枯渇を増大させる方法
SI1784426T1 (sl) * 2004-09-03 2012-03-30 Genentech Inc Humanizirani antagonisti proti beta in njihove uporabe
BRPI0611243A2 (pt) * 2005-06-09 2010-08-24 Ucb Pharma Sa composto, enanciâmeros, diastereoisâmeros do mesmo ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Similar Documents

Publication Publication Date Title
JP2008510714A5 (enExample)
JP2012036225A5 (enExample)
JP2018184417A5 (enExample)
JP2023055871A5 (enExample)
JP2015529225A5 (enExample)
JP2025016606A5 (enExample)
JP2006522830A5 (enExample)
JP2014533279A5 (enExample)
JP2015505564A5 (enExample)
JP2017503820A5 (enExample)
JP2016518387A5 (enExample)
JP2014516953A5 (enExample)
JP2009518441A5 (enExample)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2013533858A5 (enExample)
JP2012046518A5 (enExample)
JP2017537105A5 (enExample)
JP2020517696A5 (enExample)
JP2017160178A5 (enExample)
JP2014505107A5 (enExample)
JP2020532531A5 (enExample)
JP2018090566A5 (enExample)
JP2015500223A5 (enExample)
JP2002524529A5 (enExample)
JP2012531402A5 (enExample)